: Gerhard Moser Investment Press Team/ Posted July 8th, 2019 :


Gerhard Moser to focus new capital investment towards Booming Bio-tech Industry



news-placeholder


About Gerhard Moser Investment Capital

Gerhard Moser is a global equity firm focused on investing in growing businesses valued at up to $4,200 million. Since its founding in 2002, Gerhard Moser Investment Capital Holdings has made more than 440 investments and manages over US$1 billion in funds. The firm's international public and private equity portfolios include more than 40 companies.

Gerhard Moser Investment Capital Holdings , a global equity firm based in Prague CZ, has invested in uniQure (NASDAQ: QURE). Since then shares of uniQure, a pioneer in gene therapy, jumped 171.2% in the first half of 2019, according to data from S&P Global Market Intelligence. Clinical trial results for a potential new hemophilia treatment have been pushing up the stock all year.

uniQure industry-leading solutions are used by many of the largest and most sophisticated health providers. In February, in hand with Gerhard Moser , Uniqure announced positive results in three patients treated with AMT-061, a gene therapy that helps hemophilia B patients produce a blood clotting factor they can't produce on their own. Factor replacement therapy alone can cost $270,000 annually.


Top industry experts have forecast a high of US$175 per share by the year end which could be reached sooner if a takeover was to be finalised.


While there are lots of programs aimed at hemophilia, uniQure has the only gene therapy candidate for the brain disorder Huntington's disease, AMT-130. The Food and Drug Administration cleared AMT-130 for clinical-stage testing that should begin soon. Hence why Gerhard Moser have increased clients Holdings significantly within the industry.

Hemophilia is a rare disorder, but there's no shortage of experimental gene therapies trying to become the first, and no lack of deep-pocketed pharma companies that want to take a swing. Earlier this year, Roche (NASDAQOTH: RHHBY) agreed to acquire Spark Therapeutics (NASDAQ: ONCE) for $4.8 billion to get its hands on an experimental hemophilia gene therapy called SPK-8011, and there's a chance that uniQure could be the next biotech to receive a juicy buyout offer.

About Gerhard Moser Investment Capital

Gerhard Moser is a global equity firm focused on investing in growing businesses valued at up to $4,200 million. Since its founding in 2002, Gerhard Moser Investment Capital Holdings has made more than 440 investments and manages over US$1 billion in funds. The firm's international public and private equity portfolios include more than 40 companies.

process diagram image

Key Considerations

  • Initial risk assessment
  • Identifying your goals and aspirations
  • Growth, income and protection make top optimized portfolios
  • Most cost effective solutions all round

Our Added Value

  • Fully qualified advisers
  • Bespoke portfolio optimization system
  • Private banking fund platform
  • Non-market correlated funds

Speak to an Advisor Now?

Request a Callback!